Unspecified GLP-1
Sold by Joey Med · Injection, vial · every unspecified glp-1 record
Recorded initial charges
First month
$199
first month, including required fees on record. The published monthly rate excludes one-time and annual fees; introductory and conditional rates may change. Some fee details are unverified or unpublished; this sum does not establish the full amount payable.
| Medication · GLP-1 Core plan · recorded initial monthly payment | $199 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| GLP-1 Core plan “GLP-1 Core — Injection A GLP-1 Core plan designed to support weight management, appetite control, and metabolic balance with weekly injections. Prescribed if clinically appropriate. Choose weeks/plan $279 / $199” | Per month$199 | Charged today$199 |
Price sources
- GLP-1 Core plan · joeymed.com — read September 2026
We earn nothing from this link. It opens Joey Med's website without a paid referral.
History
Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.
- September 2026 — Entry added to the register
Sourcing and terms
| States | All 50 states |
|---|---|
| Prescriber | Both |
| Cancellation | Refunds are initiated within 15 business days from the date of your Consultation outcome. |
Not yet checked: pharmacy, membership and consult fee.
Recorded from joeymed.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2026 — None of the three weight-loss plan pages ever name a specific active ingredient in their visible text — 'GLP-1 Core', 'GLP-1 Plus Core', and 'GLP-1 Plus Core High Dose' are all described only as generic 'GLP-1' with weekly injections, so all three are recorded as 'unspecified GLP-1' rather than assigned to semaglutide or tirzepatide. Notably the third plan's own URL slug is /weight-loss/tirz-hd (apparently short for 'tirzepatide high dose'), which strongly implies the drug, but per the brief's rule that a fact must appear in the printed page text, the URL alone was not treated as confirmation — the page body itself never says 'tirzepatide.' Each plan's pricing line reads 'Choose weeks/plan $[higher] / $[lower]' without stating whether the lower number is a monthly price, a one-time introductory price, or price-per-a-specific-number-of-weeks (the phrase 'Choose weeks/plan' suggests a week-count selector whose exact terms aren't resolved in static text) — recorded at term:1 as the closest reading but flagged as uncertain. Prescriber model is explicitly disclosed as either synchronous or asynchronous depending on the encounter, a rare direct answer. State coverage is asserted broadly as all 50 states in both the page title and body copy.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.